Tyra Biosciences price target raised to $53 from $37 at Wedbush

14 hours ago 4

TipRanks

Sat, February 14, 2026 astatine 8:05 AM CST 1 min read

Wedbush expert Robert Driscoll raised the firm’s terms people connected Tyra Biosciences (TYRA) to $53 from $37 and keeps an Outperform standing connected the shares. The steadfast notes BridgeBio (BBIO) announced affirmative topline Phase 3 information for infigratinib successful achondroplasia, providing validation for FGFR3 inhibition arsenic an on-target mechanics for tallness velocity increases successful skeletal dysplasia patients. Wedbush views this information arsenic peculiarly encouraging for dabogratinib, arsenic a much selective FGFR3 inhibitor volition apt show important further increases successful implicit AHV, with imaginable for important and clinically important changes successful proportionality.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected TYRA:

Disclaimer & DisclosureReport an Issue

Tyra Biosciences participates successful a coferejce telephone with William Blair
Tyra Biosciences initiated with an Outperform astatine William Blair
Tyra Biosciences Advances BEACH301 Dose Escalation
Tyra Biosciences terms people raised to $50 from $36 astatine Oppenheimer
Tyra Biosciences initiated with an Overweight astatine Barclays

Read Entire Article